|Bid||2.2800 x 1000|
|Ask||2.5400 x 800|
|Day's Range||2.2900 - 2.3700|
|52 Week Range||1.6900 - 13.5200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
NEW YORK, May 13, 2022--PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO.
NEW YORK, May 11, 2022--Lucid Diagnostics provides business update and preliminary first quarter 2022 financial results.
NEW YORK, May 09, 2022--Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard® DNA test to over 8 million covered lives.